Navigation Links
Natural anti-viral enzyme helps keep cancer cells alive, researchers find

A molecule that cells normally use to fight viruses is also involved in keeping cancer cells alive, researchers at UT Southwestern Medical Center have discovered.

The anti-viral molecule, called TBK-1, was found to be essential for cancer cells to live, so blocking it might point to a treatment for fighting cancer, the researchers report in today's issue of Cell.

"We got the surprise that this mechanism is involved in cancer cell survival, even though it's normally involved in immune response," said Dr. Michael White, associate professor of cell biology. "We found something a little bit different ?an Achilles' heel of cancer cells that's apparently broadly conserved among many types of solid tumors."

Using cultured human cells, the researchers set out to study enzymes known to be involved in keeping cancer cells alive and proliferating. They soon narrowed the focus to one called RalB. This molecule is part of the Ras family of enzymes, which are mutated in 30 percent of all cancers and in 90 percent of pancreatic cancers.

The UT Southwestern scientists knew that RalB interacts with a protein complex called the exocyst, which helps small secretory packets in cells fuse to the cell membrane. The team isolated this complex, then chemically analyzed the proteins attached to it.

One protein they found on the exocyst, TBK-1, is known to be involved in cells' anti-viral response.

"There was nothing known about that mechanism to suggest how TBK-1 could drive cancer cell survival," Dr. White said.

The researchers found that TBK-1 is turned off in healthy cells unless the immune response is stimulated but was always active in the cancerous cells they studied. When they blocked the function of TBK-1 in both the cancerous and healthy cells, cancer cells died while healthy cells survived.

A German research team has studied clinical samples of tumors and found elevated levels of TBK-1, Dr. White said.


'"/>

Source:UT Southwestern Medical Center


Page: 1 2

Related biology news :

1. Genetically Modified Natural Killer Immune Cells Attack, Kill Leukemia Cells
2. Natural Killers Could Lead to New Hepatitis Treatments
3. Natural tumor suppressor in body discovered by UCSD medical researchers
4. Naturally occurring asbestos linked to lung cancer
5. Natural compound from pond scum shows potential activity against Alzheimers
6. Natural selection at single gene demonstrated
7. Natural vitamin E tocotrienol reaches blood at protective levels
8. Natural pine bark extract relieves muscle cramp and pain in athletes and diabetics
9. Natural protein stops deadly human brain cancer in mice
10. Natural polyester makes new sutures stronger, safer
11. Natural gut hormone offers hope for new obesity drug
Post Your Comments:
Breaking Biology News(10 mins):Synthetic protein mimics structure, function of metalloprotein in nature 2First phase of pan-tropical forest mapping debuting at COP15 2First phase of pan-tropical forest mapping debuting at COP15 3Potential new heart attack biomarker uncovered 2Anglo Americans Coal Division in South Africa Wins Global Business Coalition Award for top International Workplace HIV and AIDS Programme 49753 1Anglo Americans Coal Division in South Africa Wins Global Business Coalition Award for top International Workplace HIV and AIDS Programme 49753 2Anglo Americans Coal Division in South Africa Wins Global Business Coalition Award for top International Workplace HIV and AIDS Programme 49753 3Derma Sciences Announces First Commercial Sales of BIOGUARD 28TM 29 Barrier Dressings 49751 1Derma Sciences Announces First Commercial Sales of BIOGUARD 28TM 29 Barrier Dressings 49751 2Derma Sciences Announces First Commercial Sales of BIOGUARD 28TM 29 Barrier Dressings 49751 3Derma Sciences Announces First Commercial Sales of BIOGUARD 28TM 29 Barrier Dressings 49751 4Biovista Inc Announces Positive Efficacy Results in a Pre Clinical Trial of its BVA 601 Repositioned Drug for Epilepsy 12744 1Biovista Inc Announces Positive Efficacy Results in a Pre Clinical Trial of its BVA 601 Repositioned Drug for Epilepsy 12744 2